- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 110117-83-4] Indoximod
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-16724 |
| Brand: | MCE |
| CAS: | 110117-83-4 |
Overview
| MDL | MFCD00274271 |
|---|---|
| Molecular Weight | 218.25 |
| Molecular Formula | C12H14N2O2 |
| SMILES | N[C@H](CC1=CN(C)C2=CC=CC=C12)C(O)=O |
5 Publications Citing Use of MCE
Summary
IC50 & Target
|
IDO 19 μM (Ki) |
In Vitro
The IDO inhibitor 1-methyl-tryptophan exists in two stereoisomers with potentially different biological properties. The L isomer is the more potent inhibitor of IDO activity using the purified enzyme and in HeLa cell–based assays. However, the D isomer is significantly more effective in reversing the suppression of T cells created by IDO-expressing dendritic cells. The L isomer of 1-methyl-tryptophan functioned as a competitive inhibitor (K i =19 μM), whereas the d isomer is much less effective. The DL mixture is intermediate, with a K i of 35 μM [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
The D isomer is more efficacious as an anticancer agent in chemo-immunotherapy regimens using NSC-26271, NSC 125973, or LY 188011, when tested in mouse models of transplantable melanoma and transplantable and autochthonous breast cancer. The D isomer of 1-methyl-tryptophan specifically targets the IDO gene because the antitumor effect of d-1-methyl-tryptophan is completely lost in mice with a disruption of the IDO gene (IDO-knockout mice). Oral administration of dl-1-methyl-tryptophan in combination with NSC 125973 can elicit regression of autochthonous breast tumors [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03852446 | NewLink Genetics Corporation|Lumos Pharma |
Healthy
|
March 5, 2018 | Early Phase 1 |
| NCT03301636 | NewLink Genetics Corporation|Lumos Pharma |
Melanoma
|
December 8, 2017 | Phase 2 |
| NCT04049669 | Theodore S. Johnson|National Cancer Institute (NCI)|Augusta University|Emory University |
Glioblastoma|Medulloblastoma|Ependymoma|Diffuse Intrinsic Pontine Glioma
|
October 2, 2019 | Phase 2 |
| NCT01191216 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
September 2010 | Phase 1 |
| NCT02502708 | NewLink Genetics Corporation|Lumos Pharma |
Glioblastoma Multiforme|Glioma|Gliosarcoma|Malignant Brain Tumor|Ependymoma|Medulloblastoma|Diffuse Intrinsic Pontine Glioma|Primary CNS Tumor
|
October 2015 | Phase 1 |
| NCT02835729 | NewLink Genetics Corporation|Lumos Pharma |
Acute Myeloid Leukemia
|
July 2016 | Phase 1 |
| NCT02460367 | NewLink Genetics Corporation|Lumos Pharma |
Non-small Cell Lung Cancer|Progression of Non-small Cell Lung Cancer|Non-small Cell Lung Cancer Recurrent
|
January 2016 | Phase 1 |
| NCT02073123 | NewLink Genetics Corporation|Lumos Pharma |
Metastatic Melanoma|Stage III Melanoma|Stage IV Melanoma
|
July 2014 | Phase 1|Phase 2 |
| NCT05106296 | Theodore S. Johnson|Augusta University |
Ependymoma|Medulloblastoma|Glioblastoma|Primitive Neuroectodermal Tumor (PNET)
|
February 8, 2022 | Phase 1 |
| NCT01042535 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) |
Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
December 28, 2009 | Phase 1|Phase 2 |
| NCT01560923 | Masonic Cancer Center, University of Minnesota |
Metastatic Prostate Cancer
|
October 1, 2012 | Phase 2 |
| NCT03372239 | NewLink Genetics Corporation|Lumos Pharma |
Healthy
|
November 21, 2017 | Phase 1 |
| NCT01792050 | NewLink Genetics Corporation|Lumos Pharma |
Metastatic Breast Cancer
|
February 2013 | Phase 2 |
| NCT00739609 | NewLink Genetics Corporation|Lumos Pharma |
Breast Cancer|Lung Cancer|Melanoma|Pancreatic Cancer|Solid Tumors
|
August 2008 | Phase 1 |
| NCT02052648 | NewLink Genetics Corporation|Lumos Pharma |
Glioblastoma Multiforme|Glioma|Gliosarcoma|Malignant Brain Tumor
|
March 2014 | Phase 1|Phase 2 |
| NCT02077881 | NewLink Genetics Corporation|Lumos Pharma |
Metastatic Pancreatic Adenocarcinoma|Metastatic Pancreatic Cancer
|
August 2014 | Phase 1|Phase 2 |
| NCT01302821 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI) |
Breast Cancer
|
January 2013 | Not Applicable |
| NCT00567931 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
October 2007 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : 5 mg/mL ( 22.91 mM ; ultrasonic and adjust pH to 2 with HCl)
DMSO : 0.55 mg/mL ( 2.52 mM ; Need ultrasonic and warming)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.5819 mL | 22.9095 mL | 45.8190 mL |
| 5 mM | 0.9164 mL | 4.5819 mL | 9.1638 mL |
| 10 mM | 0.4582 mL | 2.2910 mL | 4.5819 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 1 mg/mL (4.58 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
References
- [1] Hou DY, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophancorrelates with antitumor responses. Cancer Res. 2007 Jan 15;67(2):792-801.
- [2] Metz R, et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012;1(9):1460-1468.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.